

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Canceled).
2. (Currently Amended) The target binding protein of claim ~~4~~ 42 or 43, wherein said first scFv and said first immunoglobulin-like domain are linked via a first extra amino acid sequence, and wherein said second scFv and said second immunoglobulin-like domain are linked via a second extra amino acid sequence.
3. (Previously Presented) The target binding protein of claim 2, wherein said first extra amino acid sequence associates with said second extra amino acid sequence.
4. (Previously Presented) The target binding protein of claim 3, wherein said first extra amino acid sequence associates with said second extra amino acid sequence via at least one disulfide bond.
5. (Currently Amended) The target binding protein of claim 2, wherein said first immunoglobulin-like domain comprises an immunoglobulin light chain variable region domain ~~or a derivative thereof~~, wherein said first extra amino acid sequence comprises an immunoglobulin light chain constant region domain ~~or a derivative thereof~~, wherein said second immunoglobulin-like domain comprises an immunoglobulin heavy chain variable region domain ~~or a derivative thereof~~, and wherein said second extra amino acid sequence comprises an immunoglobulin heavy chain constant region domain ~~or a derivative thereof~~.
6. (Previously Presented) The target binding protein of claim 5, wherein said first immunoglobulin-like domain comprises an immunoglobulin light chain variable region domain, wherein said first extra amino acid sequence comprises an immunoglobulin light chain constant region domain, wherein said second immunoglobulin-like domain comprises an immunoglobulin heavy chain variable region domain, and wherein said second extra amino acid sequence comprises an immunoglobulin heavy chain constant region domain.
7. (Previously Presented) The target binding protein of claim 5, wherein the first scFv and the immunoglobulin light chain constant region domain are linked via a first peptide linker, and wherein the second scFv and the immunoglobulin heavy chain constant region domain are linked via a second peptide linker.

8. (Previously Presented) The target binding protein of claim 7, wherein the first peptide linker comprises the amino acid sequence EPKSADKTHTCPPCPGGGS (SEQ ID NO: 1), and wherein the second peptide linker comprises the amino acid sequence EPKSCDKTHTCPPCPGGGS (SEQ ID NO: 2).
9. (Currently Amended) The target binding protein of claim-~~1~~ 42 or 43, wherein at least two of the three target binding sites have different target binding specificities.
10. (Currently Amended) The target binding protein of claim-~~1~~ 42 or 43, wherein at least two of the three target binding sites have the same target binding specificity.
11. (Currently Amended) The target binding protein of claim-~~1~~ 42 or 43, wherein the first polypeptide or the second polypeptide is linked to an additional amino acid sequence at either the N- or C-terminus thereof.
12. (Previously Presented) The target binding protein of claim 11, wherein said additional amino acid sequence comprises a polypeptide selected from the group consisting of a peptide tag, a signal peptide, an enzyme, a cytokine, a toxin, a drug and a cytotoxic protein.
13. (Canceled).
14. (Canceled).
15. (Currently Amended) The target binding protein of claim-~~1~~ 42 or 43, wherein the carbohydrate chain is linked to an agent selected from the group consisting of a drug, a radioactive compound, a chelate, an enzyme, a toxin, a cytokine and a cytotoxic protein.
16. (Currently Amended) The target binding protein of claim-~~1~~ 42 or 43, wherein the target binding protein is conjugated to an agent selected from the group consisting of a drug, a radioactive compound, a chelate, an enzyme, a toxin, a cytokine and a cytotoxic protein.
17. (Currently Amended) The target binding protein of claim-~~1~~ 42 or 43, wherein one target binding site is capable of binding to a toxin, a drug, a cytokine, a chelate, an enzyme, a radioactive compound or a cytotoxic protein, and wherein the other two target binding sites are capable of binding to tumor antigens.
18. (Currently Amended) The target binding protein of claim-~~1~~ 42 or 43, wherein one target binding site is capable of binding to a tumor antigen, and wherein the other two target binding sites are capable of binding to toxins, drugs, cytokines, chelates, enzymes, radioactive compounds or cytotoxic proteins.

19. (Currently Amended) The target binding protein of claim ~~1~~ 42 or 43, wherein one target binding site is capable of binding to a tumor antigen, and the other two target binding sites are capable of binding to surface proteins of a T cell or another effector cell.

20. (Previously Presented) The target binding protein of claim 19, wherein said surface proteins of a T cell are CD28 and CD3.

21. (Withdrawn) An isolated nucleic acid molecule comprising a polynucleotide encoding the first polypeptide of claim 1.

22. (Withdrawn) A vector comprising the nucleic acid of claim 21.

23. (Withdrawn) A host cell comprising the vector of claim 22.

24. (Withdrawn) A host cell comprising a first and second vector, wherein said first vector comprises a first nucleic acid which comprises a first polynucleotide encoding the first polypeptide of claim 1, and wherein said second vector comprises a second nucleic acid which comprises a second polynucleotide encoding the second polypeptide of claim 1.

25. (Withdrawn) A method of producing a target binding protein, comprising culturing the host cell of claim 24 in a suitable medium, and separating said target binding protein from said medium.

26. (Withdrawn) An isolated nucleic acid molecule comprising a polynucleotide encoding the second polypeptide of claim 1.

27. (Withdrawn) A vector comprising the nucleic acid of claim 26.

28. (Withdrawn) A host cell comprising the vector of claim 27.

29. (Withdrawn) An isolated nucleic acid molecule comprising a polynucleotide encoding the first and second polypeptides of claim 1.

30. (Withdrawn) A vector comprising the nucleic acid of claim 29.

31. (Withdrawn) A host cell comprising the vector of claim 30.

32. (Withdrawn) A method of producing a target binding protein, comprising culturing the host cell of claim 31 in a suitable medium, and separating said target binding protein from said medium.

33. (Withdrawn) A method of eliciting an immune response against a tumor, comprising administering to a subject an effective amount of the target binding protein of claim 19.

34. (Withdrawn) A method of eliciting an immune response against a tumor, comprising administering to a subject an effective amount of the target binding protein of claim 20.

35. (Withdrawn) A method of treating or detecting a tumor in a subject, comprising administering to said subject an effective amount of the target binding protein of claim 17.

36. (Withdrawn) A method of treating or detecting a tumor in a subject, comprising administering to said subject an effective amount of the target binding protein of claim 18.

37. (Withdrawn) A method of treating or detecting a tumor in a subject, comprising administering to said subject an effective amount of the target binding protein of claim 12, wherein at least one target binding site of the target binding protein binds to a tumor antigen.

38. (Withdrawn) A method of treating or detecting a tumor in a subject, comprising administering to said subject an effective amount of the target binding protein of claim 15, wherein at least one target binding site of the target binding protein binds to a tumor antigen.

39. (Withdrawn) A method of treating or detecting a tumor in a subject, comprising administering to said subject an effective amount of the target binding protein of claim 16, wherein at least one target binding site of the target binding protein binds to a tumor antigen.

40. (Withdrawn) A method of treating a tumor in a subject in need of treatment thereof, comprising

- a. administering to said subject the target binding protein of claim 1; and
- b. administering to said subject a pharmaceutically effective amount of a cytotoxic agent.

41. (Withdrawn) The method of claim 40, further comprising reducing the amount of said target binding protein from said subject prior to administering said cytotoxic agent.

42. (New) A target binding protein comprising two polypeptides,  
wherein the first polypeptide comprises a light chain of a Fab or Fab' fused to a first scFv,  
wherein the second polypeptide comprises a heavy chain of a Fab or Fab' fused to a second scFv;  
wherein said Fab or Fab' heavy and light chains form a binding site and wherein said first and said second scFvs each form a binding site, wherein:

at least one of said binding sites binds to a tumor marker,  
at least one of said binding sites binds to a hapten, and  
wherein at least one of said Fab or Fab' heavy or light chains comprises a constant region N-glycosylation recognition sequence; and wherein a carbohydrate chain is linked to said N-glycosylation recognition sequence.

43. (New) A target binding protein comprising two polypeptides,  
wherein the first polypeptide comprises a light chain of a Fab or Fab' fused to a first scFv,  
wherein the second polypeptide comprises a heavy chain of a Fab or Fab' fused to a second scFv;  
wherein said Fab or Fab' heavy and light chains form a binding site and wherein said first and said second scFvs each form a binding site, wherein:  
at least one of said binding sites is selected from the Fv of mAb hMN14,  
at least one of said binding sites is selected from the Fv of mAb 734, and  
wherein at least one of said Fab or Fab' heavy or light chains comprises a constant region N-glycosylation recognition sequence; and wherein a carbohydrate chain is linked to said N-glycosylation recognition sequence.